Home > Treatment Support and Financial Assistance

Treatment Support and Financial Assistance

With SOMAVERT®, patients receive comprehensive support services

Pfizer offers comprehensive services for your patients, including financial assistance for eligible patients, if needed. You can enroll your patients by calling the Pfizer Bridge Program®* at 1-800-645-1280, or fax a completed Statement of Medical Necessity (SMN) to 1-800-479-2562.

The Pfizer Bridge Program® offers personalized reimbursement support throughout therapy. SOMAVERT® patients have access to personalized support, provided by a dedicated Patient Care Consultant (PCC) from the Pfizer Bridge Program who works directly with your patients and with you.

Dedicated PCC Support

  • The PCC serves as coordinating liaison among patient, insurance company, and pharmacy
  • The same PCC works with your patients and you from SMN initiation through authorization
  • Each PCC is knowledgeable about regional payers and individual plans
  • Your patient's PCC helps research coverage for SOMAVERT® when your patient's insurance changes

Quick Approval Turnaround

  • 7 days average time to approval

Continuing Support

  • Patients receive regular check-in calls from the PCC to offer support for insurance needs and check coverage status
  • The PCC proactively calls patients to help avoid interruptions/discontinuation of treatment

Patient Assistance Program

  • Qualified uninsured or underinsured patients receive medication and supplies

SOMAVERT Starter Kit
To help new patients begin SOMAVERT therapy, Pfizer supplies a kit containing several helpful tools. These include a SOMAVERT Injection Placemat, Patient Brochure, injection training DVD, and an initial supply of syringes for injecting SOMAVERT (when a prescription is provided).

Injection Training
Patients can get one-on-one in-home training by qualified nurses. To request training for your patient during enrollment, simply check the “Patient Injection Training Requested” box on the SOMAVERT Statement of Medical Necessity.

*Certain programs and services powered by Pfizer RxPathwaysTM.
Includes new patients as of April 2014.

SOMAVERT® (pegvisomant for injection) is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels.

IMPORTANT SAFETY INFORMATION FOR SOMAVERT

SOMAVERT is contraindicated in patients with a history of hypersensitivity to any of its components.

Patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.

Patients with acromegaly and diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of treatment with SOMAVERT.

Important safety information regarding liver test monitoring
Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with SOMAVERT. Monitor liver tests based on baseline values and changes during therapy according to the schedule in the full Prescribing Information.

Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in <2% of subjects among two open-label trials (with a total of 147 patients). These reports were not associated with an increase in bilirubin. Transaminase elevations normalized with time, most often after suspending treatment. If a patient develops liver test elevations, or any other symptoms of liver dysfunction while receiving SOMAVERT, please see Liver Tests section of the full Prescribing Information.

In subjects with systemic hypersensitivity reactions, caution and close monitoring should be exercised when re-initiating SOMAVERT therapy.

The most common adverse events (>6% and at frequencies greater than placebo) in 1 of the 3 active treatment arms in a placebo-controlled study (N=112) included infection (23%), pain (14%), nausea (14%), diarrhea (14%), abnormal liver function tests (12%), flu syndrome (12%), and injection-site reaction (11%).

Lipohypertrophy has been reported in patients treated with SOMAVERT; therefore, injection sites should be rotated daily.

The maximum indicated daily maintenance dose for SOMAVERT is 30 mg.

Rx only


Please scroll for Important Safety Information and Indication

INDICATION

SOMAVERT® (pegvisomant for injection) is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels.

IMPORTANT SAFETY INFORMATION FOR SOMAVERT

SOMAVERT is contraindicated in patients with a history of hypersensitivity to any of its components.

Patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.

Patients with acromegaly and diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of treatment with SOMAVERT.

Important safety information regarding liver test monitoring
Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with SOMAVERT. Monitor liver tests based on baseline values and changes during therapy according to the schedule in the full Prescribing Information.

Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in <2% of subjects among two open-label trials (with a total of 147 patients). These reports were not associated with an increase in bilirubin. Transaminase elevations normalized with time, most often after suspending treatment. If a patient develops liver test elevations, or any other symptoms of liver dysfunction while receiving SOMAVERT, please see Liver Tests section of the full Prescribing Information.

In subjects with systemic hypersensitivity reactions, caution and close monitoring should be exercised when re-initiating SOMAVERT therapy.

The most common adverse events (>6% and at frequencies greater than placebo) in 1 of the 3 active treatment arms in a placebo-controlled study (N=112) included infection (23%), pain (14%), nausea (14%), diarrhea (14%), abnormal liver function tests (12%), flu syndrome (12%), and injection-site reaction (11%).

Lipohypertrophy has been reported in patients treated with SOMAVERT; therefore, injection sites should be rotated daily.

The maximum indicated daily maintenance dose for SOMAVERT is 30 mg.

Rx only